ASK120067

DRUG4 trials

Sponsors

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorLocally Advanced or Metastatic NSCLC

Phase 1

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Jiangsu Aosaikang Pharmaceutical Co., Ltd.Locally Advanced or Metastatic NSCLC

Start: 2017-11-30End: 2021-08-31Target: 507Updated: 2020-09-16

Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects

CompletedNCT04360915

Jiangsu Aosaikang Pharmaceutical Co., Ltd.Locally Advanced or Metastatic NSCLC

Start: 2019-12-09End: 2019-12-30Updated: 2020-04-29

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

RecruitingNCT05306132

Jiangsu Aosaikang Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2022-08-08End: 2027-12-31Target: 150Updated: 2025-12-23

Phase 3

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Active, not recruitingNCT04143607

Jiangsu Aosaikang Pharmaceutical Co., Ltd.Locally Advanced or Metastatic NSCLC

Start: 2019-07-23End: 2026-09-30Updated: 2024-06-14

Related Papers

Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.

2025-06-204 citations

Abstract CT118: Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors

Cancer Research2024-04-05

Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study

Journal of Thoracic Oncology2022-06-0125 citations

Efficacy and safety of ASK120067 (limertinib) in patients with locally advanced or metastatic EGFR T790M-mutated non–small cell lung cancer: A multicenter, single-arm, phase IIb study.

Journal of Clinical Oncology2022-06-013 citations